|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ann Thorac Surg 2005;79:1383
© 2005 The Society of Thoracic Surgeons
Department of Surgery, University of Alabama at Birmingham, 1530 3rd Ave S, ZRB 719, Birmingham, AL 352940007, USA
wholman@its.uab.edu
| The first 20% of the full text of this article appears below. |
Recent Food and Drug Administration approval for the CardioWest total artificial heart (TAH) (SynCardia Systems, Tucson, AZ) and ongoing investigational use of the AbioCor TAH (Abiomed, Danvers, MA) are important developmental milestones for this type of mechanical circulatory support. There are advantages that TAHs have over ventricular assist devices (VADs), but there are also two important challenges that are inherent to the TAH concept. First, a TAH must be highly reliable, as the patient's native heart is removed; and second, it must fit within the relatively confined space (especially the anteriorposterior dimension) of the human chest. Schenk and associates address the second of these problems with a novel TAH that
This article has been cited by other articles:
![]() |
S. Schenk, S. Weber, W. A. Smith, and K. Fukamachi MagScrew Total Artificial Heart Ann. Thorac. Surg., June 1, 2006; 81(6): 2338 - 2339. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |